Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Constellation Brands
STZ
5
Cars.com
CARS
US Stock MarketDetailed Quotes
ANAB AnaptysBio
- 18.060
- -0.530-2.85%
Trading Apr 1 09:50 ET
553.84MMarket Cap-3.53P/E (TTM)
18.640High18.000Low19.79KVolume18.550Open18.590Pre Close362.44KTurnover0.11%Turnover RatioLossP/E (Static)30.67MShares41.30852wk High7.81P/B325.66MFloat Cap12.21052wk Low--Dividend TTM18.03MShs Float134.000Historical High--Div YieldTTM3.44%Amplitude10.000Historical Low18.315Avg Price1Lot Size
About AnaptysBio Company
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Company Profile
SymbolANAB
Company NameAnaptysBio
Listing DateJan 26, 2017
Issue Price15.00
Founded2005
CEOMr. Daniel R. Faga
MarketNASDAQ
Employees136
Fiscal Year Ends12-31
Address10770 Wateridge Circle,Suite 210
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121-5801
Phone1-858-362-6295
Websitehttp://www.anaptysbio.com
Company Executives
- Name
- Position
- Salary
- Daniel R. Faga
- Director, President and Chief Executive Officer
- 7.46M
- Paul F. Lizzul, M.D.
- Chief Medical Officer
- 2.44M
- Eric J. Loumeau
- Chief Legal Officer
- 2.26M
- Dennis M. Mulroy
- Chief Financial Officer and Principal Accounting Officer
- --
- John A. Orwin, M.B.A.
- Chairman of the Board
- 338.08K
- Oleg Nodelman
- Independent Director
- --
- John P. Schmid
- Independent Director
- 335.38K
- Hollings C. Renton
- Independent Director
- 342.38K
- Dr. Rita I. Jain, M.D.
- Independent Director
- 495.60K
- Dr. Magda Marquet, PhD
- Independent Director
- 318.38K
- Dr. J. Anthony Ware
- Independent Director
- 338.38K
- Dr. Dennis M. Fenton,PhD
- Independent Director
- 331.88K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
